Exploring how synthetic fatty acids can fight antibiotic-resistant bacteria.
Investigating the mechanism of action of antibacterial synthetic unsaturated fatty acids in methicillin-resistant Staphylococcus aureus
This study is looking at how certain synthetic fatty acids might help fight tough infections caused by antibiotic-resistant bacteria like MRSA, with the hope of finding new treatment options that work better and reduce the risk of resistance.
Quick facts
| Grant type | R15 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Inter American University/puerto Rico NIH-funded |
| Lab location | 1 site (San Juan, United States) |
| Project ID | NIH-10793131 on NIH RePORTER |
What this research studies
This research investigates the effectiveness of synthetic unsaturated fatty acids (uFAs) in combating methicillin-resistant Staphylococcus aureus (MRSA), a type of bacteria that is resistant to many antibiotics. The study aims to understand how these fatty acids disrupt bacterial cell membranes, potentially leading to new treatments for infections that are difficult to treat with existing antibiotics. By examining the mechanisms of action of compounds like 2-hexadecynoic acid and DAT-51, the research seeks to develop more effective antibacterial agents that can work at very low concentrations. Patients may benefit from new treatment options that are less likely to lead to antibiotic resistance.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with infections caused by methicillin-resistant Staphylococcus aureus.
Not a fit: Patients with infections caused by bacteria that are not resistant to antibiotics may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new antibacterial treatments for patients suffering from MRSA infections.
How similar studies have performed: Previous research has shown promise in using synthetic fatty acids as antibacterial agents, indicating potential for success in this novel approach.
Where this research is happening
San Juan, United States
- Inter American University/puerto Rico — San Juan, United States (Active)
Researchers
- Principal investigator: Sanabria, David — Inter American University/puerto Rico
- Study coordinator: Sanabria, David
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.